• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中老年人群脑衰老生物标志物的开发与验证:深度学习方法

Development and Validation of a Brain Aging Biomarker in Middle-Aged and Older Adults: Deep Learning Approach.

作者信息

Li Zihan, Li Jun, Li Jiahui, Wang Mengying, Xu Andi, Huang Yushu, Yu Qi, Zhang Lingzhi, Li Yingjun, Li Zilin, Wu Xifeng, Bu Jiajun, Li Wenyuan

机构信息

Center for Clinical Big Data and Analytics, The Second Affiliated Hospital and Department of Big Data in Health Science, School of Public Health, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.

Department of Radiology, The First Affiliated Hospital, Zhengzhou University, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.

出版信息

JMIR Aging. 2025 Aug 1;8:e73004. doi: 10.2196/73004.

DOI:10.2196/73004
PMID:40750095
Abstract

BACKGROUND

Precise assessment of brain aging is crucial for early detection of neurodegenerative disorders and aiding clinical practice. Existing magnetic resonance imaging (MRI)-based methods excel in this task, but they still have room for improvement in capturing local morphological variations across brain regions and preserving the inherent neurobiological topological structures.

OBJECTIVE

To develop and validate a deep learning framework incorporating both connectivity and complexity for accurate brain aging estimation, facilitating early identification of neurodegenerative diseases.

METHODS

We used 5889 T1-weighted MRI scans from the Alzheimer's Disease Neuroimaging Initiative dataset. We proposed a novel brain vision graph neural network (BVGN), incorporating neurobiologically informed feature extraction modules and global association mechanisms to provide a sensitive deep learning-based imaging biomarker. Model performance was evaluated using mean absolute error (MAE) against benchmark models, while generalization capability was further validated on an external UK Biobank dataset. We calculated the brain age gap across distinct cognitive states and conducted multiple logistic regressions to compare its discriminative capacity against conventional cognitive-related variables in distinguishing cognitively normal (CN) and mild cognitive impairment (MCI) states. Longitudinal track, Cox regression, and Kaplan-Meier plots were used to investigate the longitudinal performance of the brain age gap.

RESULTS

The BVGN model achieved an MAE of 2.39 years, surpassing current state-of-the-art approaches while obtaining an interpretable saliency map and graph theory supported by medical evidence. Furthermore, its performance was validated on the UK Biobank cohort (N=34,352) with an MAE of 2.49 years. The brain age gap derived from BVGN exhibited significant difference across cognitive states (CN vs MCI vs Alzheimer disease; P<.001), and demonstrated the highest discriminative capacity between CN and MCI than general cognitive assessments, brain volume features, and apolipoprotein E4 carriage (area under the receiver operating characteristic curve [AUC] of 0.885 vs AUC ranging from 0.646 to 0.815). Brain age gap exhibited clinical feasibility combined with Functional Activities Questionnaire, with improved discriminative capacity in models achieving lower MAEs (AUC of 0.945 vs 0.923 and 0.911; AUC of 0.935 vs 0.900 and 0.881). An increasing brain age gap identified by BVGN may indicate underlying pathological changes in the CN to MCI progression, with each unit increase linked to a 55% (hazard ratio=1.55, 95% CI 1.13-2.13; P=.006) higher risk of cognitive decline in individuals who are CN and a 29% (hazard ratio=1.29, 95% CI 1.09-1.51; P=.002) increase in individuals with MCI.

CONCLUSIONS

BVGN offers a precise framework for brain aging assessment, demonstrates strong generalization on an external large-scale dataset, and proposes novel interpretability strategies to elucidate multiregional cooperative aging patterns. The brain age gap derived from BVGN is validated as a sensitive biomarker for early identification of MCI and predicting cognitive decline, offering substantial potential for clinical applications.

摘要

背景

精确评估脑老化对于神经退行性疾病的早期检测及辅助临床实践至关重要。现有的基于磁共振成像(MRI)的方法在这项任务中表现出色,但在捕捉脑区局部形态变化和保留内在神经生物学拓扑结构方面仍有改进空间。

目的

开发并验证一个融合连通性和复杂性的深度学习框架,用于准确估计脑老化,以促进神经退行性疾病的早期识别。

方法

我们使用了来自阿尔茨海默病神经成像计划数据集的5889例T1加权MRI扫描。我们提出了一种新型的脑视觉图神经网络(BVGN),它结合了基于神经生物学的特征提取模块和全局关联机制,以提供一种基于深度学习的敏感成像生物标志物。使用平均绝对误差(MAE)相对于基准模型评估模型性能,同时在外部英国生物银行数据集上进一步验证泛化能力。我们计算了不同认知状态下的脑年龄差距,并进行了多项逻辑回归,以比较其在区分认知正常(CN)和轻度认知障碍(MCI)状态时相对于传统认知相关变量的判别能力。使用纵向轨迹、Cox回归和Kaplan-Meier图来研究脑年龄差距的纵向表现。

结果

BVGN模型的MAE为2.39岁,超过了当前的先进方法,同时获得了一个可解释的显著性图和得到医学证据支持的图论。此外,其性能在英国生物银行队列(N = 34,352)上得到验证,MAE为2.49岁。源自BVGN的脑年龄差距在不同认知状态(CN与MCI与阿尔茨海默病;P <.001)之间表现出显著差异,并且在区分CN和MCI方面比一般认知评估、脑容量特征和载脂蛋白E4携带情况具有更高的判别能力(受试者操作特征曲线下面积[AUC]为0.885,而AUC范围为0.646至0.815)。脑年龄差距与功能活动问卷相结合显示出临床可行性,在MAE较低的模型中判别能力有所提高(AUC为0.945,而分别为0.923和0.911;AUC为0.935,而分别为0.900和0.881)。BVGN识别出的脑年龄差距增加可能表明在从CN到MCI进展过程中的潜在病理变化,每增加一个单位与CN个体认知下降风险高55%(风险比 = 1.55,95%可信区间1.13 - 2.13;P =.006)以及MCI个体增加29%(风险比 = 1.29,95%可信区间1.09 - 1.51;P =.002)相关。

结论

BVGN为脑老化评估提供了一个精确的框架,在外部大规模数据集上表现出强大的泛化能力,并提出了新颖的可解释性策略以阐明多区域协同老化模式。源自BVGN的脑年龄差距被验证为早期识别MCI和预测认知下降的敏感生物标志物,具有巨大的临床应用潜力。

相似文献

1
Development and Validation of a Brain Aging Biomarker in Middle-Aged and Older Adults: Deep Learning Approach.中老年人群脑衰老生物标志物的开发与验证:深度学习方法
JMIR Aging. 2025 Aug 1;8:e73004. doi: 10.2196/73004.
2
Predicting cognitive decline: Deep-learning reveals subtle brain changes in pre-MCI stage.预测认知衰退:深度学习揭示轻度认知障碍前阶段大脑的细微变化。
J Prev Alzheimers Dis. 2025 May;12(5):100079. doi: 10.1016/j.tjpad.2025.100079. Epub 2025 Feb 6.
3
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
4
Hyperconnectivity and Connectome Gradient Dysfunction of Cerebello-Thalamo-Cortical Circuitry in Alzheimer's Disease Spectrum Disorders.阿尔茨海默病谱系障碍中小脑-丘脑-皮质回路的超连接性和连接组梯度功能障碍
Cerebellum. 2025 Feb 6;24(2):43. doi: 10.1007/s12311-025-01792-4.
5
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).¹⁸F - 氟代脱氧葡萄糖正电子发射断层显像(¹⁸F - FDG PET)用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2.
6
MarkVCID cerebral small vessel consortium: II. Neuroimaging protocols.马克 VCID 脑小血管联盟:二、神经影像学协议。
Alzheimers Dement. 2021 Apr;17(4):716-725. doi: 10.1002/alz.12216. Epub 2021 Jan 21.
7
Longitudinal structural MRI-based deep learning and radiomics features for predicting Alzheimer's disease progression.基于纵向结构磁共振成像的深度学习和影像组学特征预测阿尔茨海默病进展
Alzheimers Res Ther. 2025 Aug 7;17(1):182. doi: 10.1186/s13195-025-01827-2.
8
Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).血浆和脑脊液β淀粉样蛋白用于诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD008782. doi: 10.1002/14651858.CD008782.pub4.
9
Brain Age Prediction: Deep Models Need a Hand to Generalize.脑龄预测:深度模型需要助力以实现泛化。
Hum Brain Mapp. 2025 Aug 1;46(11):e70254. doi: 10.1002/hbm.70254.
10
MarkVCID cerebral small vessel consortium: I. Enrollment, clinical, fluid protocols.马克 VCID 脑小血管联盟:一、入组、临床、液体方案。
Alzheimers Dement. 2021 Apr;17(4):704-715. doi: 10.1002/alz.12215. Epub 2021 Jan 21.

本文引用的文献

1
Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials.阿尔茨海默病神经影像学计划概述及未来临床试验
Alzheimers Dement. 2025 Jan;21(1):e14321. doi: 10.1002/alz.14321. Epub 2024 Dec 22.
2
Brain aging patterns in a large and diverse cohort of 49,482 individuals.大脑在一个拥有 49482 名个体的大型且多样化队列中的老化模式。
Nat Med. 2024 Oct;30(10):3015-3026. doi: 10.1038/s41591-024-03144-x. Epub 2024 Aug 15.
3
Structure-function coupling in macroscale human brain networks.宏观人类大脑网络中的结构-功能耦合。
Nat Rev Neurosci. 2024 Oct;25(10):688-704. doi: 10.1038/s41583-024-00846-6. Epub 2024 Aug 5.
4
Mild Cognitive Impairment Progression and Alzheimer's Disease Risk: A Comprehensive Analysis of 3553 Cases over 203 Months.轻度认知障碍的进展与阿尔茨海默病风险:对3553例患者长达203个月的综合分析
J Clin Med. 2024 Jan 17;13(2):518. doi: 10.3390/jcm13020518.
5
Connectomes for 40,000 UK Biobank participants: A multi-modal, multi-scale brain network resource.4 万英国生物银行参与者的连接组学:一种多模态、多尺度脑网络资源。
Neuroimage. 2023 Dec 1;283:120407. doi: 10.1016/j.neuroimage.2023.120407. Epub 2023 Oct 14.
6
Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti-Amyloid-β Therapy.阿尔茨海默病患者接受抗β淀粉样蛋白治疗后的淀粉样相关影像学异常。
Radiographics. 2023 Sep;43(9):e230009. doi: 10.1148/rg.230009.
7
Neuroimaging and machine learning for studying the pathways from mild cognitive impairment to alzheimer's disease: a systematic review.神经影像学和机器学习在研究从轻度认知障碍到阿尔茨海默病的途径中的应用:系统综述。
BMC Neurol. 2023 Aug 22;23(1):309. doi: 10.1186/s12883-023-03323-2.
8
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics.抗淀粉样蛋白单克隆抗体是具有变革性的治疗方法,重新定义了阿尔茨海默病的治疗方法。
Drugs. 2023 May;83(7):569-576. doi: 10.1007/s40265-023-01858-9. Epub 2023 Apr 15.
9
A tripartite view of the posterior cingulate cortex.后扣带皮层的三分观点。
Nat Rev Neurosci. 2023 Mar;24(3):173-189. doi: 10.1038/s41583-022-00661-x. Epub 2022 Dec 1.
10
Brain age vector: A measure of brain aging with enhanced neurodegenerative disorder specificity.脑龄向量:一种增强神经退行性疾病特异性的大脑老化测量指标。
Hum Brain Mapp. 2022 Nov;43(16):5017-5031. doi: 10.1002/hbm.26066. Epub 2022 Sep 12.